Skip to main content
FDA Shortage Check

Is Duramorph (Morphine Sulfate Injection) in shortage?

Label: plusbeauxjours · shortage label · not a prescription, not a pharmacy, not FDA

IN SHORTAGE

Duramorph: in shortage (FDA, Oct 24)

Injections (vials)
A generic injection, not your medicine. We draw dosage forms, not products, and never pills you could match to yours.
  • Reason: “Demand increase for the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Reason: “Discontinuation of the manufacture of the drug”. FDA shortage reason (FDASIA), reported by the manufacturer
  • Estimate: “Estimated recovery: TBD”. Manufacturer’s estimate, Fresenius Kabi USA, LLC, Oct 15, 2026
DRUG
Duramorph
FDA LISTING
FORM
injection
STATUS
Currently in Shortage
FIRST POSTED
Oct 31, 2017
LAST FDA UPDATE
Oct 21, 2026
AS OF
Oct 24, 2026
SOURCE

FDA lists 24 presentations: 6 unavailable · 2 limited · 16 available.

FDA Drug Shortages checked Oct 24, 2026, 21:05 ET · FDA updates daily · manufacturer-reported

Information from FDA’s drug shortage list, reported by manufacturers. Not medical advice. Don’t stop, change or ration a medicine without talking to your prescriber or pharmacist.

FDA's listing, word for word: Morphine Sulfate Injection. 24 presentations from 5 makers.

Check your own medication, form and strength

What to ask at the counter

  1. Is this a supply problem at this pharmacy, or everywhere? Could another pharmacy have it? FDA consumer FAQ (opens in a new tab)
  2. Is my strength or the maker you stock affected? FDA list, by presentation
  3. Is there an alternative to this medicine I should ask my prescriber about? FDA consumer FAQ (opens in a new tab)
  4. When should I check back, or can you order it?

FDA: “talk with your health care provider or pharmacist for other treatment options during the shortage.” FDA Drug Shortages page (opens in a new tab)

This listing on FDA ↗ (opens in a new tab)Report a shortage to FDA: drugshortages@fda.hhs.gov

Every presentation FDA lists, by maker

Availability is FDA's text for each package, as the manufacturer reported it. Makers with unavailable or limited packages come first.

Fresenius Kabi USA, LLC6 presentations · 2 unavailable · 4 available or not stated

Contact (FDA's listing): 888-386-1300

  • 4 mg/1 mL

    Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)

    Next release November 2026. Check wholesalers for inventory.

    NDC 63323-454-01Reverified

    Unavailable

  • 5 mg/1 mL

    Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)

    Estimated recovery: TBD

    NDC 63323-455-01Reverified

    Unavailable

  • 10 mg/1 mL

    Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)

    Check wholesalers for inventory

    NDC 63323-451-01Reverified

    Available

  • 2 mg/1 mL

    Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)

    Check wholesalers for inventory

    NDC 63323-452-01Reverified

    Available

  • 2 mg/1 mL

    Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)

    Check wholesalers for inventory

    NDC 76045-004-11Reverified

    Available

  • 4 mg/1 mL

    Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)

    Check wholesalers for inventory

    NDC 76045-005-11Reverified

    Available

Hikma Pharmaceuticals USA, Inc.7 presentations · 1 unavailable · 6 available or not stated

Contact (FDA's listing): 800-631-2174

  • 10 mg/1 mL

    Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)

    Additional lots will be available in the November 2026 timeframe. Product will be made available as it is released.

    NDC 0641-6039-01Revised

    Unavailable

  • .5 mg/1 mL

    Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6020-10Reverified

    Available

  • 1 mg/1 mL

    Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6019-10Reverified

    Available

  • 25 mg/1 mL

    Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6040-01Reverified

    Available

  • 10 mg/1 mL

    Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6127-25Revised

    Available

  • 4 mg/1 mL

    Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6125-25Reverified

    Available

  • 8 mg/1 mL

    Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)

    Additional lots are scheduled to be manufactured. Product will be made available as it is released.

    NDC 0641-6126-25Revised

    Available

Hospira, Inc., a Pfizer Company8 presentations · 3 unavailable · 2 limited · 3 available or not stated

Contact (FDA's listing): 844-646-4398

  • 10 mg/1 mL Syringes

    Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)

    Discontinuation of the manufacture of the drug

    NDC 0409-1893-01Reverified

    Unavailable

  • 50 mg/1 mL

    Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)

    Next Delivery: February 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-1896-20Revised

    Unavailable

  • 50 mg/1 mL

    Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01)

    Next Delivery: February 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-2022-01Revised

    Unavailable

  • 10 mg/10 mL (1 mg/mL)

    Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)

    Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-3815-12Revised

    Limited Availability

  • 2 mg/1 mL

    Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23)

    Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay

    NDC 0409-1890-23Revised

    Limited Availability

  • 2 mg/1 mL Syringes

    Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)

    NDC 0409-1890-01Reverified

    Available

  • 4 mg/1 mL Syringes

    Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)

    NDC 0409-1891-01Reverified

    Available

  • 5 mg/10 mL (0.5 mg/mL)

    Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)

    NDC 0409-3814-12Reverified

    Available

Amphastar Pharmaceuticals, Inc.1 presentation · 1 available or not stated

Contact (FDA's listing): 800-423-4136

  • 1 mg/1 mL

    Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)

    NDC 76329-1912-1Reverified

    Available

Piramal Critical Care Inc.2 presentations · 2 available or not stated

Contact (FDA's listing): 800-414-1901

  • 200 mg/20 mL

    Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)

    NDC 66794-160-02Revised

    Available

  • 500 mg/20 mL

    Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)

    NDC 66794-162-02Reverified

    Available

What the manufacturers told FDA

  • Fresenius Kabi USA, LLC · ‘Estimated recovery: TBD’ · updated Oct 2026
  • Fresenius Kabi USA, LLC · ‘Next release November 2026. Check wholesalers for inventory.’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026
  • Hospira, Inc., a Pfizer Company · ‘Next Delivery: February 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay’ · updated Oct 2026

More on FDA ↗ (opens in a new tab)

Reason for the shortage (FDASIA)

  • Demand increase for the drug
  • Discontinuation of the manufacture of the drug
  • Other

As reported by the manufacturer under the Food and Drug Administration Safety and Innovation Act.

Shown as FDA status, not as suggestions.

Alternatives

FDA lists none: “Providing a list of alternative drug products for a drug in shortage is part of the ‘practice of medicine.’ FDA does not regulate the practice of medicine.” Your prescriber or pharmacist can talk through options with you. ASHP also tracks shortages and suggested alternatives (different criteria) ↗ (opens in a new tab)

Questions

Is Duramorph in shortage?
Yes. As of Oct 24, 2026, FDA lists Morphine Sulfate Injection as currently in shortage: 24 presentations, 6 unavailable and 2 limited.
When will the Duramorph shortage end?
FDA gives no end date. 5 presentations carry a manufacturer’s own estimate, quoted on this page with its date.
Does FDA list alternatives to Duramorph?
No. FDA calls a list of alternatives part of the ‘practice of medicine’. Ask your pharmacist or prescriber.